Recent advances in herpes simplex virus antiviral therapies

Bibliography

• ROIZMAN B: Herpesviridae. In: Fields Virology BN Fields, DM Knipe and PM Howley (Eds), Lippincott-Raven Publishers, Philadelphia (1996):2221–2230.
   Google Scholar
• •General reference textbook.
   Google Scholar
• KLEYMANN G: Novel agents and strategies to treat herpes simplex virus infections. Expert Opin. Investig. Drugs. (2003) 12:165–183.
   PubMed Web of Science ®Google Scholar
• ••Excellent review highlighting the field ofanti-HSV drugs.
   Google Scholar
• WHITLEY RJ, GNANN JW: The epidemiology and clinical manifestations of herpes simplex virus infections. In: The Human Herpesviruses. B Roizman, RI Whitley, C Lopez (Eds), Raven Press, New York (1993):69–105
   Google Scholar
• BREN L: Genital herpes: a hidden epidemic. FDA consum. (2002) 36:10–16.
   PubMedGoogle Scholar
• CRUMPACKER CS, SCHAFFER PA: New anti-HSV therapeutics target the helicase-primase complex. Nat. Med. (2002) 8:327–328.
   PubMed Web of Science ®Google Scholar
• ••News article highlighting the excitingdevelopment of the helicase-primase inhibitors.
   Google Scholar
• COEN DM, SCHAFFER PA: Antiherpesvirus drugs: a promising spectrum of new drugs and drug targets. Nat. Rev Drug Discov. (2003) 2:278–288.
   PubMed Web of Science ®Google Scholar
• VILLARREAL EC: Current and potential therapies for the treatment of herpes-virus infections. Frog. Drug Res. (2003) 60:263–307.
   PubMedGoogle Scholar
• ELION GB, FURMAN PA, FYFE JA et al: Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine. Proc. Natl. Acad. Sci USA (1977) 74:5716–5720.
   PubMed Web of Science ®Google Scholar
• GILBERT C, BESTMAN-SMITH J, BOIVIN G: Resistance of herpesviruses to antiviral drugs: clinical impacts and molecular mechanisms. Drug Resist. Updat. (2002) 5:88–114.
   PubMed Web of Science ®Google Scholar
• KLEYMANN G: New antiviral drugs thattarget herpesvirus helicase primase enzymes. Herpes (2003) 10:46–52.
   PubMedGoogle Scholar
• BOEHMER PE, LEHMAN IR: Herpes simplex virus DNA replication. Ann. Rev Biochem. (1997) 66:347–384.
   PubMed Web of Science ®Google Scholar
• •Good discussion of the biochemistry of DNA replication in HSV.
   Google Scholar
• BOEHMER PE, NIMONKAR AV: Herpes virus replication. IUBMB Life (2003) 55:13–22.
   PubMed Web of Science ®Google Scholar
• LEHMAN IR, BOEHMER PE: Replication of herpes simplex virus DNA. Biol. Chem. (1999) 274:28059–28062.
   Google Scholar
• FALKENBERG M, LEHMAN IR, ELIAS P: Leading and lagging strand DNA synthesis M vitro by a reconstituted herpes simplex virus type 1 replisome. Proc. Natl. Acad. Sci. USA. (2000) 97:3896–900.
   PubMedGoogle Scholar
• WEISSHART K, KUO AA, HWANG CB, KUMURA K, COEN DM: Structural and functional organization of herpes simplex virus DNA polymerase investigated by limited proteolysis. J. Biol. Chem. (1994) 269:22788–22796.
   PubMedGoogle Scholar
• HUANG L, ISHII KK, ZUCCOLA H et al.: The enzymological basis for resistance of herpesvirus DNA polymerase mutants to acyclovir: relationship to the structure of alpha-like DNA polymerases. Proc. Natl. Acad. Sci. USA (1999) 96:447–452.
   PubMedGoogle Scholar
• DIGARD P, BEBRINWR, WEISSHART K, COEN DM: The extreme C terminus of herpes simplex virus DNA polymerase is crucial for functional interaction with processivity factor UL42 and for viral replication.' Vita (1993) 67:398–406.
   Google Scholar
• WEISSHART K, CHOW CS, COEN DM: Herpes simplex virus processivity factor UL42 imparts increased DNA-binding specificity to the viral DNA polymerase and decreased dissociation from primer-template without reducing the elongation rate.' Vim]. (1999) 73:55–66.
   Google Scholar
• WATHEN MW: Non-nucleoside inhibitors of herpesviruses. Rev. Med. Virol (2002) 12:167–178.
   PubMed Web of Science ®Google Scholar
• •Good overview of the non-nucleoside inhibitors of HSV DNA polymerase.
   Google Scholar
• VAILLANCOURT VA, CUDAHY MM, STALEY SA et al.: Naphthalene carboxamides as inhibitors of human cytomegalovirus DNA polymerase. Bioorg. Med. Chem. Let. (2000) 10:2079–2081.
   PubMed Web of Science ®Google Scholar
• OIEN NL, BRIDEAU RI, HOPKINS TA et al: Broad-spectrum antiherpes activities of 4-hydroxyquinoline carboxamides, a novel class of herpesvirus polymerase inhibitors. Antimicrob. Agents Chemother. (2002) 46:724–730.
   PubMed Web of Science ®Google Scholar
• BRIDEAU RI, KNECHTEL ML, HUANG A et al.: Broad-spectrum antiviral activity of PNU-183792, a 4-oxo-dihydroquinoline, against human and animal herpesviruses. Antivira/Res. (2002) 54:19–28.
   PubMed Web of Science ®Google Scholar
• ••Excellent discussion of the design andmechanism of action of the non-nucleoside inhibitors of DNA polymerase.
   Google Scholar
• THOMSEN DR, OIEN NL, HOPKINS TA et al.: Amino acid changes within conserved region III of the herpes simplex virus and human cytomegalovirus DNA polymerases confer resistance to 4-oxo-dihydroquinolines, a novel class of herpesvirus antiviral agents. J . Vim]. (2003) 77:1868-187 6.
   Google Scholar
• ••This paper discusses the binding of non-nucleoside inhibitors to DNA polymerase.
   Google Scholar
• DE CLERCQ E: Guanosine analogues as anti-herpesvirus agents. Nucleoside. Nucleotide. Nucleic Adds. (2000) 19:1531–1541.
   PubMed Web of Science ®Google Scholar
• WANG J, FROEYEN M, HENDRIX C et al: The cyclohexene ring system as a furanose mimic: synthesis and antiviral activity of both enantiomers of cyclohexenylguanine. Med. Chem. (2000) 43:736–745.
   Google Scholar
• GRAVES-WOODWARD KL, GOTTLIEB J, CHALLBERG MD, WELLER SK: Biochemical analyses of mutations in the HSV-1 helicase-primase that alter ATP hydrolysis, DNA unwinding, and coupling between hydrolysis and unwinding. j. Biol. Chem. (1997) 272:4623–4630.
   PubMed Web of Science ®Google Scholar
• KLEYMANN G, FISCHER R, BETZ UA et al.: New helicase-primase inhibitors as drug candidates for the treatment of herpes simplex disease. Nat. Med. (2002) 8:392–398.
   PubMed Web of Science ®Google Scholar
• ••A key paper outlining the discovery of oneclass of helicase-primase inhibitors.
   Google Scholar
• CRUTE JJ, GRYGON CA, HARGRAVE KD et al.: Herpes simplex virus helicase-primase inhibitors are active in animal models of human disease. Nat. Med. (2002) 8:386–391.
   PubMed Web of Science ®Google Scholar
• ••A key paper outlining the discovery of oneclass of helicase-primase inhibitors.
   Google Scholar
• KLEYMANN G: Helicase-primase inhibitors. Drugs Fut. (2003) 28:257–265.
   Web of Science ®Google Scholar
• BETZ UA, FISCHER R, KLEYMANN G, HENDRIX MR, UBSAMEN-WAIGMANN H: Potent in vivo antiviral activity of the herpes simplex virus primase-helicase inhibitor BAY-571293. Antimicrob. Agents Chemother: (2002) 46:1766–1772.
   Google Scholar
• HERNANDEZ TR, LEHMAN IR: Functional interaction between the herpes simplex-1 DNA polymerase and UL42 protein. Biol. Chem. (1990) 265:11227–11232.
   Google Scholar
• WEISSHART K, CHOW CS, COEN DM: Herpes simplex virus processivity factor UL42 imparts increased DNA-binding specificity to the viral DNA polymerase and decreased dissociation from primer-template without reducing the elongation rate. J. Vim]. (1999) 73:55–66.
   Google Scholar
• CHAUDHURI M, SONG L, PARRIS DS: The herpes simplex virus type 1 DNA polymerase processivity factor increases fidelity without altering pre-steady-state rate constants for polymerization or excision. Biol . Chem. (2003) 278:8996–9004.
   Google Scholar
• BRIDGES KG, CHOW CS, COEN DM: Identification of crucial hydrogen-bonding residues for the interaction of herpes simplex virus DNA polymerase subunits via peptide display, mutational, and calorimetric approaches. Vim]. (2001) 75:4990–4998.
   Google Scholar
• THORNTON KE, CHAUDHURI M, MONAHAN SJ, GRINSTEAD LA, PARRIS DS: Analysis of in vitro activities of herpes simplex virus type 1 UL42 mutant proteins: correlation with in vivo function. Virology (2000) 275:373–390.
   PubMedGoogle Scholar
• BRIDGES KG, HUA Q, BRIGHAM -BURKE MR et al: Secondary structure and structure-activity relationships of peptides corresponding to the subunit interface of herpes simplex virus DNA polymerase. J. Biol. Chem. (2000) 275:472–478.
   PubMedGoogle Scholar
• ZUCCOLA HJ, FILMAN DJ, COEN DM, HOGLE JM: The crystal structure of an unusual processivity factor, herpes simplex virus UL42, bound to the C terminus of its cognate polymerase. MM. Cell (2000) 5:267–278.
   PubMed Web of Science ®Google Scholar
• PILGER BD, CUI C, COEN DM: Identification of a small molecule that inhibits herpes simplex virus dna polymerase subunit interactions and viral replication. Chem. Biol. (2004) 11:647–654.
   PubMed Web of Science ®Google Scholar
• PEARSON CE, ZORBAS H, PRICE GB, ZANNIS-HADJOPOULOS M: Inverted repeats, stem-loops, and cruciforms: significance for initiation of DNA replication. Biochem. (1996) 63:1–22.
   Google Scholar
• SHLYAKHTENKO LS, HSIEH P, GRIGORIEV M et al.: A cruciform structural transition provides a molecular switch for chromosome structure and dynamics. Mo/. Bid (2000) 296:1169–1173.
   PubMedGoogle Scholar
• SPEAR PG: Herpes simplex virus: receptors and ligands for cell entry. Cell Microbiol (2004) 6:401–410.
   PubMed Web of Science ®Google Scholar
• TERRY-ALLISON T, MONTGOMERY RI, WHITBECK JC et al.: HveA (herpesvirus entry mediator A), a coreceptor for herpes simplex virus entry, also participates in virus-induced cell fusion. Vim]. (1998) 72:5802–5810.
   Google Scholar
• WHITBECK JC, PENG C, LOU H et al.: Glycoprotein D of herpes simplex virus (HSV) binds directly to HVEM, a member of the tumor necrosis factor receptor superfamily and a mediator of HSV entry. Vim]. (1997) 71:6083–6093.
   Google Scholar
• VOGT VM: Ubiquitin in retrovirus assembly: actor or bystander? Proc. Natl. Acad. Sci. USA (2000) 97:12945–12947.
   PubMed Web of Science ®Google Scholar
• CRAVEN RC, HARTY RN, PARAGAS J, PALESE P, WILLS JVV: Late domain function identified in the vesicular stomatitis virus M protein by use of rhabdovirus-retrovirus chimeras. .1 Virol (1999) 73:3359–3365.
   PubMedGoogle Scholar
• PUFFER BA, PARENT LJ, WILLS JVV, MONTELARO RC: Equine infectious anemia virus utilizes a YXXL motif within the late assembly domain of the Gag p9 pmtein.j Vim]. (1997) 71:6541–6546.
   Google Scholar
• PUFFER BA, WATKINS SC, MONTELARO RC: Equine infectious anemia virus Gag polyprotein late domain specifically recruits cellular AP-2 adapter protein complexes during virion assembly. Vim ]. (1998) 72:10218–10221.
   Google Scholar
• BULTMANN H, BRANDT CR: Peptides containing membrane-transiting motifs inhibit virus entry. J. Biol. Chem. (2002) 277:36018–36023.
   PubMed Web of Science ®Google Scholar
• BEAUDET-MILLER M, ZHANG R, DURKIN J et al.: Virus-specific interaction between the human cytomegalovirus major capsid protein and the C terminus of the assembly protein precursor. Vim]. (1996) 70:8081–8088.
   Google Scholar
• HONG Z, BEAUDET-MILLER M, DURKIN J, ZHANG RK, WONG AD: Identification of a minimal hydrophobic domain in the herpes simplex virus Type 1 scaffolding protein which is required for interaction with the major capsid protein.Vim]. (1996)70:533–540.
   Google Scholar
• BOULWARE SL, BRONSTEIN JC, NORDBY EC, WEBER PC: Identification and characterization of a benzothiophene inhibitor of herpes simplex virusType 1 replication which acts at the immediate early stage of infection. Antiviral Res. (2001) 51:111–125.
   PubMed Web of Science ®Google Scholar
• HAMILTON HW, NISHIGUCHI G, HAGEN SE et al.: Novel benzthiodiazepinones as antiherpetic agents: SAR improvement of therapeutic index by alterations of the seven-membered ring. Bioorg. Med. Chem. Lett. (2002) 12:2981–2983.
   PubMedGoogle Scholar
• PYLES RB, THOMPSON RL: Evidence that the herpes simplex virusType 1 uracil DNA glycosylase is required for efficient viral replication and latency in the murine nervous system. Vim]. (1994) 68:4963–4972.
   Google Scholar
• BRIK A, WONG CH: HIV-1 protease: mechanism and drug discovery. Org. Biomol Chem. (2003) 1:5–14.
   PubMed Web of Science ®Google Scholar
• WAXMAN LD, ARKE PL: The herpesvirus proteases as targets for antiviral chemotherapy. Antivir: Chem. Chemother. (2000) 11:1–22.
   PubMed Web of Science ®Google Scholar
• TESHIMA T, GRIFFIN JC, POWERS JC: A new class of heterocyclic serine protease inhibitors. Inhibition of human leukocyte elastase, porcine pancreatic elastase, cathepsin G, and bovine chymotrypsin A-a with substituted benzoxazinones, quinazolines, and anthranilates.j. Biol. Chem. (1982) 257:5085–5091.
   Google Scholar
• STEIN RL, STRIMPLER AM, VISCARELLO BR et al.: Mechanism for slow-binding inhibition of human leukocyte elastase by valine-derived benzoxazinones. Biochemistry (1987) 26:4126–4130.
   PubMed Web of Science ®Google Scholar
• FRANKLIN TJ, EDWARDS G, HEDGE P: Inosine Y-monophosphate dehydrogenase as a chemotherapeutic target. Adv. Exp. Med. Biol. (1994) 370:155–160.
   PubMedGoogle Scholar
• ZIMMERMANN AG, GU JJ, LALIBERTE J, MITCHELL BS: Inosine-Y-monophosphate dehydrogenase: regulation of expression and role in cellular proliferation and T lymphocyte activation. Frog. Nucleic Acid Res. MM. Biol. (1998) 61:181–209.
   PubMed Web of Science ®Google Scholar
• EVERS DL, BREITENBACH JM, BORYSKO KZ, TOWNSEND LB, DRACH JC: Inhibition of cyclin-dependent kinase 1 by purines and pyrrolo [2,3-d]pyrimidines does not correlate with antiviral activity. Antimicrob. Agents Chemother. (2002) 46:2470–2476.
   PubMed Web of Science ®Google Scholar
• MORFIN F, THOUVENOT D: Herpes simplex virus resistance to antiviral drugs. Clin. Viral. (2003) 26:29–37.
   PubMed Web of Science ®Google Scholar